INmune Bio Inc
NASDAQ:INMB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
INmune Bio Inc
NASDAQ:INMB
|
US |
|
Premia Finance SpA Societa di Mediazione Creditizia
F:81U
|
IT |
|
M3 Inc
TSE:2413
|
JP |
|
Atlanta Braves Holdings Inc
F:E450
|
US |
|
FibroGen Inc
NASDAQ:FGEN
|
US |
|
S
|
Software AG
DUS:SOW
|
DE |
|
G
|
Genpact Ltd
XBER:35G
|
BM |
|
VEEM Ltd
ASX:VEE
|
AU |
|
Aures Technologies SA
PAR:AURS
|
FR |
|
Huaneng Power International Inc
SSE:600011
|
CN |
|
H
|
Healthcare Services Group Inc
SWB:HS1
|
US |
|
A
|
Allied Critical Metals Inc
CNSX:ACM
|
CA |
|
Imugene Ltd
F:ILA
|
AU |
|
Chimerix Inc
NASDAQ:CMRX
|
US |
|
P
|
Pinnacle West Capital Corp
LSE:0KIT
|
US |
Wall St Price Targets
INMB Price Targets Summary
INmune Bio Inc
According to Wall Street analysts, the average 1-year price target for
INMB is 7.14 USD with a low forecast of 4.04 USD and a high forecast of 9.45 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is INMB's stock price target?
Price Target
7.14
USD
According to Wall Street analysts, the average 1-year price target for
INMB is 7.14 USD with a low forecast of 4.04 USD and a high forecast of 9.45 USD.
What is the Revenue forecast for INmune Bio Inc?
Projected CAGR
208%
The compound annual growth rate for Revenue over the next 8 years is 208%.